Hospital-acquired Pneumonia (HAP) Drugs Market Size, Share and Growth Outlook, 2026

Hospital-acquired Pneumonia (HAP) Drugs Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Hospital-acquired Pneumonia (HAP) Drugs Market size is forecast to increase from $804.77 Million in 2026 to $1127.06 Million in 2034 at a CAGR of 4.3% between 2026 and 2034.

The Hospital-acquired Pneumonia (HAP) Drugs market report provides detailed analysis and outlook of Hospital-acquired Pneumonia (HAP) Drugs segments including By Drug Class (Antibiotics, Beta-lactamase Inhibitor Combinations, Supportive Care Drugs), By Pathogen Type (Gram-Negative Bacterial Infections, Gram-Positive Bacterial Infections ), By Route of Administration (Intravenous, Oral), By End-User (Hospitals & Intensive Care Units, Long-term Care Facilities, Retail & Specialty Pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Hospital-Acquired Pneumonia (HAP) Drugs Industry Overview

Rising Antimicrobial Resistance Driving Innovation in HAP Therapeutics

The hospital-acquired pneumonia drugs industry continues to evolve as healthcare systems confront increasing rates of multidrug-resistant bacterial infections in acute care and intensive care environments. Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia remain significant clinical challenges due to the growing prevalence of resistant Gram-negative pathogens and limited treatment options. Pharmaceutical developers are focusing on targeted antimicrobial therapies, novel antibiotic combinations, and precision treatment strategies designed to improve outcomes against highly resistant organisms. At the same time, global healthcare organizations are supporting the development of next-generation antibacterial agents through regulatory guidance and research initiatives aimed at addressing unmet clinical needs.

Novel Antibiotics Expanding Treatment Options for Resistant Infections

Advanced antimicrobial therapies are playing an increasingly important role in the management of severe hospital-acquired respiratory infections. Shionogi presented extensive real-world evidence demonstrating the effectiveness of Fetroja (cefiderocol) in treating severe infections caused by metallo-β-lactamase-producing Enterobacterales. Clinical findings showed substantial rates of clinical cure and positive overall treatment response, reinforcing the drug’s importance in managing hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Additional clinical evidence highlighted cefiderocol’s effectiveness against Chryseobacterium indologenes, a rare opportunistic pathogen characterized by intrinsic resistance to many conventional beta-lactam antibiotics. Antimicrobial susceptibility testing confirmed favorable activity, supporting successful treatment outcomes in highly vulnerable hospital populations.

Clinical Development Pipeline Strengthening Future Treatment Landscape

The industry pipeline continues to expand with therapies targeting multidrug-resistant pathogens responsible for severe respiratory infections. BioVersys initiated patient enrollment in the pivotal Phase 3 RIV-TARGET trial evaluating BV100, an investigational antibiotic combination specifically developed for infections caused by Acinetobacter baumannii. The therapy is designed to address carbapenem-resistant and multidrug-resistant strains frequently associated with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The advancement of targeted antibacterial candidates reflects increasing industry focus on pathogen-specific treatment approaches capable of overcoming escalating resistance challenges in critical care settings.

Prevention Strategies Complementing Antimicrobial Therapies

In addition to drug development, healthcare organizations are strengthening prevention strategies aimed at reducing the burden of hospital-acquired pneumonia. The World Health Organization released updated Target Product Profiles to guide development of antibacterial agents targeting priority multidrug-resistant Gram-negative pathogens, including Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales. Simultaneously, results from the large-scale HAPPEN study demonstrated that structured oral hygiene protocols significantly reduced the incidence of non-ventilator-associated hospital-acquired pneumonia across multiple hospitals. By lowering oral bacterial colonization, these interventions complement pharmaceutical treatments and support comprehensive infection prevention programs. Together, advances in targeted antibiotics, antimicrobial development frameworks, and preventive clinical protocols are shaping the future management of hospital-acquired respiratory infections.

Hospital-acquired Pneumonia (HAP) Drugs Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Hospital-acquired Pneumonia (HAP) Drugs market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Pfizer Inc., Merck & Co., Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc. (Mylan), AstraZeneca plc, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Theravance Biopharma, Inc.. The Hospital-acquired Pneumonia (HAP) Drugs market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Hospital-acquired Pneumonia (HAP) Drugs industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Hospital-acquired Pneumonia (HAP) Drugs Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Hospital-acquired Pneumonia (HAP) Drugs companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Hospital-acquired Pneumonia (HAP) Drugs markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Hospital-acquired Pneumonia (HAP) Drugs Market Competitive Benchmarking and Company Analysis

Leading companies in Hospital-acquired Pneumonia (HAP) Drugs industry include- Pfizer Inc., Merck & Co., Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc. (Mylan), AstraZeneca plc, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Theravance Biopharma, Inc.. The Hospital-acquired Pneumonia (HAP) Drugs market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Hospital-acquired Pneumonia (HAP) Drugs Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Hospital-acquired Pneumonia (HAP) Drugs market remains one of the strongest-performing segments in the country.
The US Hospital-acquired Pneumonia (HAP) Drugs Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Hospital-acquired Pneumonia (HAP) Drugs market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Hospital-acquired Pneumonia (HAP) Drugs industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Hospital-acquired Pneumonia (HAP) Drugs markets

Canada's strong Hospital-acquired Pneumonia (HAP) Drugs sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Hospital-acquired Pneumonia (HAP) Drugs market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Hospital-acquired Pneumonia (HAP) Drugs Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Hospital-acquired Pneumonia (HAP) Drugs market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Hospital-acquired Pneumonia (HAP) Drugs population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Hospital-acquired Pneumonia (HAP) Drugs industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Hospital-acquired Pneumonia (HAP) Drugs market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Hospital-acquired Pneumonia (HAP) Drugs sales through 2034

France Hospital-acquired Pneumonia (HAP) Drugs companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Hospital-acquired Pneumonia (HAP) Drugs Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Hospital-acquired Pneumonia (HAP) Drugs distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Hospital-acquired Pneumonia (HAP) Drugs Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Hospital-acquired Pneumonia (HAP) Drugs market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Hospital-acquired Pneumonia (HAP) Drugs industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Hospital-acquired Pneumonia (HAP) Drugs industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Hospital-acquired Pneumonia (HAP) Drugs Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Hospital-acquired Pneumonia (HAP) Drugs market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Hospital-acquired Pneumonia (HAP) Drugs market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Hospital-acquired Pneumonia (HAP) Drugs Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Hospital-acquired Pneumonia (HAP) Drugs Market Segmentation

By Drug Class
Antibiotics
Beta-lactamase Inhibitor Combinations
Supportive Care Drugs
By Pathogen Type
Gram-Negative Bacterial Infections
Gram-Positive Bacterial Infections
By Route of Administration
Intravenous
Oral
By End-User
Hospitals & Intensive Care Units
Long-term Care Facilities
Retail & Specialty Pharmacies

Top Companies in Hospital-acquired Pneumonia (HAP) Drugs Industry

Pfizer Inc.
Merck & Co., Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Viatris Inc. (Mylan)
AstraZeneca plc
Shionogi & Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Fresenius Kabi AG
Theravance Biopharma, Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025